We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Redx Pharma
Building on an impressive track-recordRedx Pharma
FY21 results: a year of continuing deliveryAllergy Therapeutics
FDA green lights VLP Peanut vaccine Phase I trialArecor Therapeutics
Formulation expertise exemplified in diabetesANGLE
FDA approval awaited, LDT data expected H122Allergy Therapeutics
Commercialising and developing a differentiated portfolioNexstim
Admirable execution on 2021 strategic goalsAvacta
AffiDX LFT sales paused to improve Omicron detectionAvacta
Consumer testing CE mark received for AffiDX LFTFutura Medical
Management update details degree of 2021 progress